<DOC>
	<DOCNO>NCT02265809</DOCNO>
	<brief_summary>Type 1 diabetes ( T1D ) common severe autoimmune disease worldwide cause body 's immune destruction insulin produce pancreatic beta cell lead insulin deficiency development elevate blood sugar . Currently , medical management T1D focus intensive insulin replacement therapy limit complication ( retinopathy , nephropathy , neuropathy ) ; nevertheless clinical outcome remain suboptimal . There intensive effort design novel immunotherapy arrest autoimmune process thereby preserve residual insulin production lead few complication well clinical outcome . Genetics part cause T1D majority gene contribute T1D produce protein involve immune regulation ( call `` tolerance '' ) . A key player immune tolerance molecule call interleukin-2 ( IL-2 ) enhance ability cell call T regulatory ( Treg ) cell suppress destruction insulin produce beta cell . Aldesleukin human recombinant IL-2 product produce recombinant DNA technology use genetically engineer E. coli strain express analogue human IL-2 gene . There substantial data suggest ultra-low dos ( ULD ) IL-2 ( aldesleukin ) arrest autoimmune mediate destruction pancreatic beta cell induction functional Treg cell . The former study `` Adaptive study IL-2 dose regulatory T cell type 1 diabetes '' ( DILT1D ) ( NCT 01827735 ) single dose mechanistic study design establish dos IL-2 ( aldesleukin ) require induce minimal Treg increase ( 0.1 fold baseline ) induce slightly large Treg increase ( 0.2 fold baseline ) ( maximal increase ) . Following DILT1D study , goal DILfrequency study use adaptive design determine optimal dose frequency ULD IL-2 ( aldesleukin ) maximize Treg function frequently inject ultra-low dos IL-2 ( aldesleukin ) . The responsiveness T1D participant particular frequency IL-2 ( aldesleukin ) administration informs frequency dose give next patient . This strategy focus improve function regulatory T cell exquisitely sensitive IL-2 ( aldesleukin ) .</brief_summary>
	<brief_title>Adaptive Study IL-2 Dose Frequency Regulatory T Cells Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>Type 1 diabetes 1870 year age Duration diabetes less 60 month diagnosis Written inform consent participate Hypersensitivity aldesleukin excipients History severe cardiac disease History malignancy within past 5 year ( exception localize carcinoma skin resect cure cervical carcinoma situ ) History concurrent use immunosuppressive agent steroids History unstable diabetes recurrent hypoglycaemia History live vaccination two week prior first treatment Active autoimmune hyper hypothyroidism Active clinical infection Major preexist organ dysfunction previous organ allograft Females pregnant , lactate intend get pregnant study Males intend father pregnancy study Donation 500 ml blood within 2 month prior aldesleukin administration Participation previous therapeutic clinical trial within 2 month prior aldesleukin administration Abnormal ECG Abnormal full blood count , chronic renal failure ( Stage 3,4,5 ) and/or evidence severely impaired liver function ( ALT/AST &gt; 3xULN screening ; alkaline phosphatase bilirubin 2xULN screening ( isolated bilirubin &gt; 2xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Interleukin 2</keyword>
	<keyword>Type 1 diabetes</keyword>
	<keyword>T regulatory cell</keyword>
	<keyword>Adaptive trial</keyword>
</DOC>